Recent patents from Opna Bio AG detail new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular cardiomyopathy, cancer, Holt-Oram syndrome, neurofibromatosis type 2, polycystic kidney and Alzheimer’s disease.
A Contineum Therapeutics Inc. patent describes a crystalline form of lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of brain cancer, glioblastoma, idiopathic pulmonary fibrosis, inflammatory disorders, multiple sclerosis, neurodegeneration, neuropathic pain and scleroderma, among others.
Work at the Korea Institute of Radiological and Medical Sciences and Korea Research Institute of Chemical Technology has led to the identification of new poly(ADP-ribose) polymerase tankyrase (TNKS) inhibitors potentially useful for the treatment of cancer.
In what represents the first patenting from Munich, Germany-based Meliodys Medical UG, its co-founder and chief executive officer Simone Sabbione describes their development of a hormone-free, local pain management approach for treating dysmenorrhea, which aims to address the condition while minimizing the occurrence of side effects.
Korean Research Institute of Bioscience and Biotechnology and Korea Research Institute of Chemical Technology have jointly developed molecular glue degraders acting as zinc finger protein Helios (IKZF2) degradation inducers. They are described as potentially useful for the treatment of cancer.
An Uppthera Inc. patent describes new proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13)-targeting moiety; they are reported to be useful for the treatment of cancer and neurological disorders.
Bristol Myers Squibb Co. has prepared and tested new Substituted benzimidazole compounds acting as Toll-like receptor 9 (TLR9) antagonists. They are reported to be useful for the treatment of fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, cancer, primary sclerosing cholangitis, idiopathic pulmonary fibrosis, inflammatory and autoimmune diseases.
Synnovation Therapeutics Inc. has patented phosphatidylinositol 3-kinase α (PI3K-α) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities).
Hemoshear Therapeutics Inc. has identified new 3-((1,1-dioxido-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)-2-fluoroacrylic acid derivatives acting as sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors.
RSS
